{
    "clinical_study": {
        "@rank": "4911", 
        "arm_group": {
            "arm_group_label": "MRgHIFU", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The goal of this project is to evaluate the safety and preliminary efficacy of ExAblate MR\n      guided focused ultrasound surgery in the treatment of soft tissue tumors of the extremities."
        }, 
        "brief_title": "Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Soft Tissue Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Soft Tissue Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objectives include assessment of the incidence and severity of adverse events associated\n      with treatment, and the accuracy of ablation by comparing the measured volume treated based\n      on MR thermometry and post-contrast non-perfused tissue calculations to the actual treated\n      volume in the resected tumor. In addition, the tissue adjacent to the treated region within\n      the tumor but outside the gross limits of the ablation will be examined histologically for\n      evidence of thermal damage."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females at least 10 years of age.\n\n          2. Patients who have benign or malignant soft tissue tumors of the extremities, flanks,\n             pelvis, or shoulders that require surgical intervention.\n\n          3. Tumor must not have been treated previously with radiation.\n\n          4. Patients (or guardians/parents) who are able and willing to give consent (and assent\n             where applicable) and able to attend all study visits.\n\n          5. Able to safely undergo MRI exam and receive mild sedation for the treatment.\n\n          6. Patient is able to tolerate being in the MRI scanner for the duration of the study.\n\n          7. Targeted tumor(s) are accessible to the ExAblate device\n\n          8. Patients in whom the targeted volume within the tumor is located deeper than 1 cm\n             from the skin\n\n          9. Targeted tumor is clearly visible by non-contrast MRI\n\n         10. Karnofsky Performance Status > 60\n\n         11. Normal platelet count and coagulation profile\n\n         12. Glomerular filtration rate > 60 ml/min\n\n        Exclusion Criteria:\n\n          1. Previous radiation treatment to the tumor.\n\n          2. Patients on dialysis.\n\n          3. Patients with acute medical condition (e.g. pneumonia, sepsis) that is expected to\n             hinder them from completing this study\n\n          4. Patients with unstable cardiac status including:\n\n               1. Unstable angina pectoris on medication\n\n               2. Patients with documented myocardial infarction within six months of protocol\n                  entry\n\n               3. Congestive heart failure requiring medication (other than diuretic)\n\n               4. Patients on anti-arrhythmic drugs\n\n          5. Severe hypertension (diastolic BP > 100 on medication)\n\n          6. Patients with contraindication for MR imaging such as implanted metallic devices that\n             are not MRI-safe, size limitations, etc\n\n          7. Patients with severe hematologic, neurologic, or other uncontrolled disease\n\n          8. Known intolerance or allergy to medications used for sedation (midazolam), analgesia\n             (fentanyl), and local and regional anesthesia (lidocaine, bupivacaine, and\n             ropivacaine)\n\n          9. Known intolerance or allergy to MR contrast agent (gadolinium chelates) including\n             advanced kidney disease\n\n             a. Pregnant and nursing patients will be excluded from the study because of a\n             contraindication to administering MRI contrast agents to these patients\n\n         10. Karnofsky Performance Score < 60\n\n         11. Severe cerebrovascular disease (multiple CVAs or CVA within 6 months)\n\n         12. Individuals who are not able or willing to tolerate the required prolonged stationary\n             position during treatment (can be up to 5 hrs of total table time)\n\n         13. Target volume in tumor is less then 1cm from neurovascular bundles, major blood\n             vessels, bowel or bladder.\n\n         14. Targeted tumors:\n\n               -  NOT visible by non-contrast MRI, OR\n\n               -  NOT accessible to ExAblate device\n\n         15. Patient not candidate for either regional anesthesia or mild sedation\n\n         16. Patient should not be part of another trial testing other Investigational Agents or\n             Devices"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965002", 
            "org_study_id": "VAR0095", 
            "secondary_id": "26667"
        }, 
        "intervention": {
            "arm_group_label": "MRgHIFU", 
            "intervention_name": "ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound (MRgHIFU)", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 16, 2013", 
        "location": {
            "contact": {
                "email": "ravedian@stanford.edu", 
                "last_name": "Raffi Avedian", 
                "phone": "650-721-2479"
            }, 
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94306"
                }, 
                "name": "Stanford University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Raffi Avedian", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities", 
        "overall_official": [
            {
                "affiliation": "Stanford University", 
                "last_name": "Raffi Avedian", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Stanford University", 
                "last_name": "Pejman Ghanouni", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be examined for changes in clinical exam, pain, and limb function, using the Musculoskeletal Tumor Society Score and the Toronto Extremity Salvage Score to compare before and after high-intensity focused ultrasound (HIFU) treatment. A safety profile will be developed for the ExAblate treatment of soft tissue tumors. All adverse events will be captured and summarized.", 
            "measure": "Safety determined by evaluating for the incidence and severity of any device related complication", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965002"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Pejman Ghanouni", 
            "investigator_title": "Assistant Professor of Radiology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "In the resected specimen, the volume of the ablated area will be determined by obtaining a digital photograph of each pathology slice. The region of interest corresponding to the ablated area will be traced, and the ablated area will be calculated for each slice, and summed to determine the volume.", 
                "measure": "Percent successful ablation or non-perfused volume (NPV)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 week"
            }, 
            {
                "description": "The percent difference in overlap of actual treated volume to other volume measures will be calculated and a nonparametric 90% coverage tolerance interval with 95% confidence will be constructed for each tumor ablation.", 
                "measure": "Accuracy of ablation volume within the tumor", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 week"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pejman Ghanouni", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}